MX2017007741A - Formulaciones de calcio y fosfato para inflamacion oral. - Google Patents

Formulaciones de calcio y fosfato para inflamacion oral.

Info

Publication number
MX2017007741A
MX2017007741A MX2017007741A MX2017007741A MX2017007741A MX 2017007741 A MX2017007741 A MX 2017007741A MX 2017007741 A MX2017007741 A MX 2017007741A MX 2017007741 A MX2017007741 A MX 2017007741A MX 2017007741 A MX2017007741 A MX 2017007741A
Authority
MX
Mexico
Prior art keywords
phosphate
calcium
liquid
formulations
oral inflammation
Prior art date
Application number
MX2017007741A
Other languages
English (en)
Inventor
Gosselin Patrick
Betancourt Aimesther
Weldon Bartholomew
Kobus Edward
Dumoulin Sandryne
Original Assignee
Valeant Pharmaceuticals Int Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valeant Pharmaceuticals Int Inc filed Critical Valeant Pharmaceuticals Int Inc
Publication of MX2017007741A publication Critical patent/MX2017007741A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere en general, a composiciones líquidas y métodos para tratar inflamación oral administrando una composición líquida a la cavidad oral. La composición líquida se prepara a partir de un polvo que contiene glicerofosfato de calcio, una o más sales de fosfato de sodio, cloruro de sodio, y opcionalmente bicarbonato de sodio y sílice. El polvo se mezcla con una cantidad de agua para formar un líquido que es supersaturado con iones de calcio y de iones de fosfato y está esencialmente libre de partículas y precipitados visibles.
MX2017007741A 2014-12-17 2015-12-15 Formulaciones de calcio y fosfato para inflamacion oral. MX2017007741A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093026P 2014-12-17 2014-12-17
PCT/CA2015/051327 WO2016095036A1 (en) 2014-12-17 2015-12-15 Formulations of calcium and phosphate for oral inflammation

Publications (1)

Publication Number Publication Date
MX2017007741A true MX2017007741A (es) 2018-05-02

Family

ID=56125518

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007741A MX2017007741A (es) 2014-12-17 2015-12-15 Formulaciones de calcio y fosfato para inflamacion oral.

Country Status (10)

Country Link
US (2) US11590165B2 (es)
EP (1) EP3233092B1 (es)
JP (1) JP6781701B2 (es)
KR (1) KR102397070B1 (es)
CN (1) CN107530374B (es)
AU (1) AU2015367208B2 (es)
BR (1) BR112017013158B1 (es)
CA (1) CA2971224C (es)
MX (1) MX2017007741A (es)
WO (1) WO2016095036A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10143635B2 (en) * 2016-02-03 2018-12-04 Forward Science Technologies, LLC Artificial saliva
US10765650B2 (en) * 2016-02-03 2020-09-08 Forward Science Technologies, LLC Artificial saliva
GR1009399B (el) * 2017-06-23 2018-11-15 Χρηστος Γεωργιου Φυτας Στοματικο διαλυμα κατα της ξηροστομιας και στοματοφαρυγγικης βλεννογονιτιδας
WO2023183556A2 (en) * 2022-03-24 2023-09-28 Amcyte Pharma, Inc. Treatment for retinal disorders

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB572352A (en) * 1944-02-26 1945-10-03 Charles Somerville Dillon Improved tooth powder or preparation
US4716035A (en) 1985-05-24 1987-12-29 The Procter & Gamble Company Oral compositions and methods for treating gingivitis
US5540913A (en) 1987-03-17 1996-07-30 Turner; Robert E. Formulations and uses thereof in the prevention and treatment of oral lesions
US5268267A (en) 1987-08-21 1993-12-07 The General Hospital Corporation Method for diagnosing small cell carcinoma
US5427768A (en) 1993-06-23 1995-06-27 American Dental Association Health Foundation Carbonated solutions for treating, mineralizing and fluoridating calcified tissues and methods for their use
JPH11500724A (ja) * 1995-02-24 1999-01-19 アメリカン デンタル アソシエイション ヘルス ファウンデーション 石灰化組織の処置、鉱化及びフッ化物化用の炭酸塩化した溶液及びその使用方法
BR9610258A (pt) 1995-08-08 2000-05-09 Enamelon Inc Produto em uma parte, estável, aquoso, para efetuar a remineralização de uma ou mais lesões, processo para remineralizar uma ou mais lesões, produto em uma parte, estável, não aquoso, e produto em duas partes, estável, aquoso, para efetuar a remineralização de uma ou mais lesões, e, produto de goma de mascar para efetuar a remineralização de uma ou mais lesões
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ATE238761T1 (de) 1996-09-18 2003-05-15 Erling Johansen Mundwasser mit kalzium- und phosphationen in einer übersättigten lösung
US6159448A (en) * 1996-09-27 2000-12-12 Enamelon, Inc. Products and methods for the remineralization and prevention of demineralization of teeth
US7838046B2 (en) * 2001-09-26 2010-11-23 Tampa Bay Research Institute Plant extracts and uses thereof
US20040248942A1 (en) * 2003-02-20 2004-12-09 Bonnie Hepburn Novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
JP4669960B2 (ja) 2003-06-03 2011-04-13 株式会社 メドレックス 局所麻酔薬を含有する口中用または咽頭部用製剤
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
EP1718303A4 (en) * 2004-02-10 2010-09-01 Santarus Inc COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG
US8518383B2 (en) * 2006-02-03 2013-08-27 Wm. Wrigley Jr. Company Oral care products comprising buffer systems for improved mineralization/remineralization benefits
WO2007117627A2 (en) * 2006-04-05 2007-10-18 Cadbury Adams Usa Llc Calcium phosphate complex and salts in oral delivery systems
TWI445540B (zh) * 2007-04-20 2014-07-21 Ajinomoto Kk 抗低體溫組成物
JP5166780B2 (ja) * 2007-06-20 2013-03-21 花王株式会社 液体口腔用組成物
WO2009012393A1 (en) * 2007-07-18 2009-01-22 The Curators Of The University Of Missouri Pharmaceutical composition comprising a proton pump inhibitor and protein component
US9358242B2 (en) * 2007-08-30 2016-06-07 Prelief Inc. Calcium glycerophosphate for treating and preventing respiratory diseases or conditions
US20090130232A1 (en) 2007-11-20 2009-05-21 Mohammed Zahra Composition and method for treatment of oral inflammation an ulceration
US20090239957A1 (en) * 2007-12-21 2009-09-24 Alcon Research, Ltd. Stabilized glycerophosphate-containing surgical irrigating solution
WO2009105568A1 (en) * 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
JP2009235012A (ja) 2008-03-28 2009-10-15 Gc Corp 口腔湿潤用組成物
WO2010054494A2 (en) 2008-11-14 2010-05-20 Profimed S.R.O. Biomimetic oral care composition
CN101584889B (zh) 2009-07-10 2012-12-12 山东大学威海分校 一种用于治疗牙周病的外用原位成型基质
US20110086108A1 (en) 2009-10-12 2011-04-14 Bartholomew Weldon Dissolving powders that can be mixed with water and used as an oral rinse
JP5485677B2 (ja) 2009-12-16 2014-05-07 花王株式会社 口腔用組成物
WO2012021415A2 (en) * 2010-08-07 2012-02-16 Research Foundation Of State University Of New York Oral compositions comprising a zinc compound and an anti-microbial agent
CA2891362C (en) * 2012-11-16 2020-04-21 Arcoral Pharma As Effervescent tablet

Also Published As

Publication number Publication date
US20160175356A1 (en) 2016-06-23
WO2016095036A1 (en) 2016-06-23
CN107530374A (zh) 2018-01-02
JP2018505862A (ja) 2018-03-01
AU2015367208A1 (en) 2017-08-03
AU2015367208B2 (en) 2021-04-01
EP3233092A1 (en) 2017-10-25
CN107530374B (zh) 2021-07-27
BR112017013158A2 (pt) 2018-04-10
EP3233092A4 (en) 2018-08-01
US11590165B2 (en) 2023-02-28
US20230241102A1 (en) 2023-08-03
CA2971224C (en) 2020-09-22
KR102397070B1 (ko) 2022-05-16
JP6781701B2 (ja) 2020-11-04
EP3233092B1 (en) 2019-09-04
CA2971224A1 (en) 2016-06-23
BR112017013158B1 (pt) 2023-05-02
KR20170105517A (ko) 2017-09-19

Similar Documents

Publication Publication Date Title
EP3603661A3 (en) Rna containing composition for treatment of tumor diseases
PH12018500987A1 (en) Dihydroimidazopyrazinone derivatives useful in the treatment of cancer
MX2020013592A (es) Composiciones para el cuidado bucal y metodos de uso.
MX2015016070A (es) Composiciones antitranspirantes.
MX2015016277A (es) Tratamiento de canceres utilizando moduladores de la isoforma pi3 cinasa.
MX2017007741A (es) Formulaciones de calcio y fosfato para inflamacion oral.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
EA201890193A1 (ru) Композиция для ухода за полостью рта
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
PH12015502368A1 (en) Antiperspirant compositions
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
AR101188A1 (es) Composiciones orales anticálculo
EA201992382A3 (ru) Пероральная таблетированная фармацевтическая композиция двойного применения на основе сульфатных солей и способы ее применения
EA201791670A1 (ru) Твердые композиции для ухода за полостью рта
EA201692149A1 (ru) Композиции для ухода за полостью рта
MX2017007622A (es) Composiciones para el cuidado bucal.
MX2018007053A (es) Estructurante de alginato de zinc sodio y metodo de fabricacion y uso de este.
SG10201810093PA (en) Pharmaceutical composition for external use
MX2016002714A (es) Composicion y metodo para tropicalizar chocolate.
EA201791653A1 (ru) Твердые композиции для ухода за полостью рта
MY186889A (en) Oral care composition
MY182809A (en) Compositions for the treatment of kidney and/or liver disease
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
MX361002B (es) Composiciones antisarro para el cuidado bucal que proporcionan la prevención de la cristalización.

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status

Owner name: FP MARANGONI INC.